New Two-year Data: Bimekizumab Provides Sustained Disease Control in HS
Bimekizumab (Bimzelx, UCB) shows sustained efficacy in moderate to severe hidradenitis suppurativa (HS), according to data from the BE HEARD trials presented at the 2025 European Hidradenitis Suppurativa Foundation conference in Vilnius, Lithuania. Bimekizumab selectively inhibit both interleukin 17A (IL-17A) and interleukin 17F (IL-17F) . Among HS patients who achieved response to bimekizumab at one […]